Topsalysin Seen to Help Some Localized Prostate Cancer Patients in Small Study

Topsalysin Seen to Help Some Localized Prostate Cancer Patients in Small Study
Some patients with localized prostate cancer were seen to benefit from treatment with topsalysin (PRX302) in a small Phase 2a proof-of-concept trial (NCT02499848), according to Sophiris Bio. Findings from the trial were presented at this year’s 112th American Urology Association meeting by Edward J. Bass, University College London. The poster was titled "Intra-Prostatic PRX302 Focal Therapy in Treating Clinically Significant Low-Intermediate Risk Prostate Cancer: An Open Label, Proof-of-Concept Study.” Topsalysin is a recombinant protein designed to be selectively activated by PSA, a protein produced in high levels by prostate cancer cells. It triggers local cell death and tissue disruption without damaging healthy, neighboring tissue. The prostate-specific activation of topsalysin by active PSA is designed to limit the exposure of non-prostate tissues to the drug’s activity, ensuring a safer treatment. The study’s objective was to assess the safety and efficacy of topsalysin injections. It enrolled 18 prostate cancer patients, who received a single injection in the prostate region affected by cancer. Patients were then followed at day two, and then at two, six, 12, 24, and 26 weeks. At week 24, researchers collected a prostate biopsy from the treated area. Follow-up data indicated that a single dose of topsalysin directly targeting pre-identified tumor cells was both safe and well-tolerated. Biopsies collected at 24 weeks after treatment showed that two patients achieve complete tumor response and
Subscribe or to access all post and page content.

Tagged , , , .

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *